..., and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] Abstract Background Although the BCR-ABL tyrosine kinase inhibitor dasatinib is a potent treatment for chronic myeloid leukaemia, it is associated with the risk...

... receptors such as platelet derived growth factor, fibroblast growth factor and vascular endothelial growth factor. Nintedanib, a tyrosine kinase inhibitor targeting primarily these receptors, is approved for the treatment of patients with idiopathic pulmonary fibrosis. Our objective was to examine...

... on the increase in thrombin receptor mRNA expression was enhanced by the protein kinase C inhibitor Ro 31-8220, but was unaffected by prolonged incubation with phorbol myristate acetate or the tyrosine kinase inhibitors genistein and erbstatin A. Conclusion: These results demonstrate that AII enhances...

... of the multidisciplinary team in this setting and communication between the cardiologists and the oncologists or haemato-oncologists is invaluable. tyrosine kinase inhibitor hypertension cardiotoxicity thrombosis QT prolongation cardiotoxicity tyrosine kinase inhibitors TKIs angiogenesis inhibitors JAK inhibitors...

... and dysfunction as a result of cachexia in patients with advanced malignancies. anthracycline trastuzumab tyrosine kinase inhibitor RAF–MEK inhibitor immune checkpoint inhibitor radiation-induced heart disease cachexia aetiology of HF anthracyclines cancer therapy related cardiac dysfunction trastuzumab...